Human adenosine deaminase (ADA; adenosine aminohydrolase, EC 3.5.4.4) was expressed at high levels in cultured mouse cells using a transmissable murine retrovirus vector system. A cDNA clone encoding ADA has been inserted into a plasmid vector containing retroviral transcription and packaging signals as well as a selectable gene for G418 resistance. The constructions were transfected into t/2 cells, which package the recombinant retroviral genomes into replication-defective virus particles. Isoenzyme analysis for ADA in G418-selected q/2 cells showed at least 20-fold more human ADA activity than endogenous mouse ADA activity. A mouse T-cell lymphoma line, BL/VL3, was cocultured with transformed tP2 cells producing human ADA, and some of the cocultured cells were selected for resistance to G418. Both G418-selected and unselected cocultured cells expressed human ADA activity at 25%-50% the level of the endogenous enzyme. Thus, efficient retroviral transduction of ADA expression was obtained.
G418-selected and unselected cocultured cells expressed human ADA activity at 25%-50% the level of the endogenous enzyme. Thus, efficient retroviral transduction of ADA expression was obtained.
Adenosine deaminase (ADA; adenosine aminohydrolase, EC 3.5.4.4) catalyzes the irreversible deamination of adenosine and deoxyadenosine. It is present in all human tissues, but lymphoid cells, particularly thymocytes, express the highest levels (1, 2) . Deficiency of ADA activity is associated with '50% of autosomal recessive cases of severe combined immunodeficiency disease (SCID) (3) (4) (5) , which is characterized by profound depletion of lymphoid tissue. The metabolic consequences of ADA deficiency have been investigated extensively (6, 7) . Based on inhibitor studies and attempts to improve immune function by adding ADA, it appears likely that ADA deficiency causes SCID (6, 7, (8) (9) (10) . Recently, several groups have isolated cDNA clones for human (11) (12) (13) and mouse (14) ADA.
It was of interest to develop a system to express ADA as a model for possible introduction of a functional ADA gene in ADA-deficient SCID. Several laboratories have now used retrovirus vector systems to introduce genes into cultured cells (15, [16] [17] [18] [19] [20] [21] [22] . Retrovirus vector systems are advantageous because retroviruses infect a wide variety of cell types and transduce genes very efficiently. The SVX vector [pZIPNeo SV(X)1] (described in ref. 23 ) was used for this work because it permits the simultaneous expression of a cDNA clone of interest and the Tn5 neo gene, which confers resistance to the antibiotic G418 to mammalian cells (24) .
The SVX vector was used in conjunction with qf2 (25) , an NIH 3T3-derived cell line that contains an endogenous Moloney murine leukemia virus (MuLV) that lacks the sequence necessary for viral RNA packaging. Thus, 42 cells provide retroviral proteins in trans for packaging and reverse transcription of SVX genomes, allowing helper-free stocks of replication-defective recombinant retroviruses to be produced. A similar packaging system has now been developed for packaging recombinant SVX genomes into viruses that will infect human cells (26) .
This paper describes the use of the SVX system to express human ADA in cultured mouse cells.
MATERIALS AND METHODS
Plasmid Construction. The retroviral expression vector pZIP-Neo SV(X)1 was generously provided by Richard Mulligan. EcoRI and EcoRI methylase, and T4 ligase were gifts from Paul Modrich and Stewart Scherer, respectively. All other enzymes were from Boehringer-Mannheim and New England Biolabs. EcoRI and BamHI adapters, and EcoRI linkers were from Collaborative Research (Waltham, MA). All manipulations were according to established techniques (27) .
Tissue Culture. The 42 cell line was a gift from Richard Mulligan and was maintained as described (25) . Mouse 3T6 and NIH 3T3 cells were provided by Paul Berg and were grown in Dulbecco's modified Eagles medium supplemented with 5% newborn calf serum and 10% calf serum, respectively. BL/VL3 cells, a radiation-induced leukemia virus (RadLV)-transformed mouse T-cell lymphoma line, were a gift from Irving Weissman and were grown as described (28) . Virus titrations were performed as described (23) . Cocultivation of qi2-derived lines with BL/VL3 cells was performed in RPMI-1640 medium supplemented with 10% fetal calf serum.
ADA Assays. Hemolysates were prepared as described (29) and extracts of tissue-culture cells were prepared as in ref. 30 except a ball-bearing homogenizer (W. E. Balch and J. E. Rothman, personal communication) was used instead of a motorized tissue grinder. Isoenzyme analysis was performed on 1% agarose gels (SeaKem Laboratories, Rockland, ME) using the buffer system and histochemical staining protocol described (29) .
RESULTS
Construction of a Retrovirus Vector to Express Human ADA. Fig. 1 shows the strategy for vector construction. The ADA 211 cDNA clone described in ref. for 3 days but not selected with G418 (CC in the figure). To ensure that there were no contaminating qiADA 2A cells, the non-adherent cells were split 1:10 into a fresh flask and cultured for 2 days to allow any contaminating fibroblasts to reattach. Microscopic examination showed that the cocultured BL/VL3 cells were not contaminated with the much larger iADA 2A cells. The isoenzyme analysis in Fig.  3 was intentionally overdeveloped so it would reproduce clearly, and the left side of the gel developed more than the right. Shorter development showed that, depending on the isolate, 25%-50% of the total ADA activity was in the human isoenzyme. There was little difference between cells that were selected with G418 and cells that were assayed without drug selection. Thus, transduction must be extremely efficient. The fact that the human enzyme constitutes only 25%-50% of the ADA activity in BL/VL3 cells does not mean that ADA expression is less efficient in BL/VL3 cells than in NIH 3T3 cells. The specific activity of the endogenous ADA in thymocyte extracts is considerably higher than that in fibroblasts (1, 2). In fact, ADA is a marker for differentiation of T-cell malignancies (34, 35) . The retroviral RNAs in the BL/VL3 transductants were analyzed to determine whether the newly integrated proviruses had a structure consistent with that predicted from the organization of pSVX-ADA 2. Fig. 4A shows an RNA blot of RNAs from f2 and frNeo cells. The 7.9-kilobase (kb) MuLV and 2.9-kb env mRNAs in 42 cells serve as convenient size standards and the lower of the two additional bands in qiNeo RNA is the spliced neo mRNA (the upper band is unspliced). (Fig. 1) , the 5.6-kb band remained in all of the ADA 2A-BL/VL3 transformants but could not be seen in untransformed BL/VL3 cells (not shown). It is clear, however, that the 5.6-kb ADA-containing mRNA is not nearly as abundant as the spliced neo mRNA.
While transduction of ADA into BL/VL3 cells by cocultivation was extremely efficient, efforts to introduce human ADA into mouse fibroblasts (3T6, NIH 3T3) by transduction with the retrovirus have not been successful. The lack of infectivity appears to be specific for ADAcontaining constructs. Greater than 104 G418-resistant 3T6 cell colony-forming units/ml are readily obtained from tissue culture supernatants from populations of frNeo cells. The infectivity of iAADA 2 supernatants is at least 2 orders of magnitude lower. Since q2 cells express a substantial level of the MuLV genomic and env mRNAs, it is not likely that inadequate production of retroviral proteins by the tf2 cells explains the poor fibroblast infectivity of ADA 2 transformants. It is also conceivable that high level expression of ADA from the LTR promoter is toxic to some mouse fibroblast cell lines. denatured, electrophoresed on a 1.2% agarose gel, and transferred to nitrocellulose as described (37) . The blots were probed with nick-translated (38) pSVX-ADA 2 DNA at a specific activity of 108 cpm/Ag and were washed as described (27) . 
